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Abstract
Background: The therapeutic HIV-1 Tat protein vaccine is in advanced clinical development. Tuberculosis, the main
AIDS co-infection, is highly endemic in areas where AIDS prevention through vaccination is needed. However,
safety and immunogenicity of Tat vaccination in the course of Mycobacterium tuberculosis (Mtb) infection is still
unknown and it prevents the possibility to administer the vaccine to Mtb-infected individuals. We addressed the
interplay and effects of Tat vaccination on Mtb infection in immunocompetent mice.
Methods: C57BL/6 mice were vaccinated or not with Bacillus Calmette-Guerin (BCG), the current tuberculosis
vaccine, and after 5 weeks were infected with Mtb by intravenous route. The Tat protein was injected intradermally
at 1, 2 and 4 weeks after Mtb challenge. Eight weeks after Mtb infection, all mice were sacrificed, and both the
degree of pathology and immune responses to Mtb and Tat were evaluated. As additional control, some mice were
either vaccinated or not with BCG, were not challenged with Mtb, but received the Tat protein. Statistical
significances were evaluated by one-way or two-way ANOVA and Tukey’s multiple comparisons post-test.
Results: In the lungs of Mtb-infected mice, Tat-vaccine did not favour Mtb replication and indeed reduced both area
of cellular infiltration and protein levels of Interferon-γ, Chemokine (C-C motif) ligand-4 and Interleukin-1β, pathological
events triggered by Mtb-infection. Moreover, the protection against Mtb infection conferred by BCG remained good
after Tat protein treatment. In spleen cells of Mtb-infected mice, Tat vaccination enhanced Mtb-specific Interferon-γ and
Interleukin-17 responses, which may have a protective role. Of note, Mtb infection reduced, but did not suppress, the
development of anti-Tat antibodies, required for Tat vaccine efficacy and the titer of anti-Tat IgG was potentiated by
BCG vaccination in Mtb-free mice. In general, Tat treatment was well tolerated in both Mtb-infected and Mtb-free mice.
Conclusions: Tat protein vaccine, administered in Mtb-infected mice with a protocol resembling that used in the
clinical trials, was safe, immunogenic, limited the lung Mtb-associated immunopathology and did not abrogate the
protective efficacy of BCG. These data provide preliminary evidence for a safe use of Tat vaccine in people vaccinated
with BCG and/or suffering from tuberculosis.
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Background
The HIV regulatory Tat protein is crucial in AIDS patho-
genesis and is a promising vaccine candidate in advanced
clinical development. Tat is the transactivator of HIV gene
expression and it is essential for viral replication, estab-
lishment of infection and virus reactivation [1, 2]. Tat is
expressed by proviral DNA prior to virus integration into
the host genome [3], and it is commonly found extracellu-
larly both during acute infection and at the time of virus
reactivation [4, 5], even in patients on effective antiretro-
viral therapy [6]. Extracellular Tat protein concurs to cell-
to-cell virus transmission, disease progression [4, 7] and
immune dysregulation [8], contributing to the chronic
immune hyperactivation and dysfunction observed in HIV
infection [3, 9].
Approaches employing biologically active Tat protein
have been shown to contain virus replication, prevent-
ing disease onset and/or progression in monkey models
[10, 11], (http://www.hiv1tat-vaccines.info). The Tat-
based vaccine has then been advanced to clinical testing
in preventative phase I, and therapeutic phase I and II
trials showing safety and immunogenicity [12–17].
Moreover, two different trials indicated that Tat vaccine
contributed to HIV-1 containment in patients on effect-
ive HAART [14, 18], (ISS T-003, ClinicalTrial.gov iden-
tifier: NCT01513135). In particular, results from an
open-label randomized exploratory therapeutic phase II
trial in 168 patients on effective HAART showed that
vaccination induced a durable and significant restor-
ation of T, B, natural killer cells, and CD4+ and CD8+
central memory subsets, as well as up-regulation of the
expression of HLA-DR+ on CD8+ killer T cells, a
phenotype found to be increased in elite controllers
[16] and to contribute to HIV-1 containment [17].
Moreover, the Tat vaccine induced a significant reduc-
tion of blood proviral DNA which was significantly
associated with anti-Tat immunoglobulin (Ig)M and
IgG antibody titers and neutralization of Tat-mediated
entry of oligomeric Env in dendritic cells [14, 18]. More
recently, a confirmatory phase II, randomized, double-
blind, placebo-controlled trial in HIV-infected, anti-Tat
antibody negative, antiretroviral-treated adult volun-
teers [18], (ISS T-003, ClinicalTrial.gov identifier:
NCT01513135) has been completed in South Africa, an
endemic region in which approximately 28 % of indi-
viduals living with HIV and tuberculosis (TB) reside
[19]. Infections caused by Mtb are the main and most
dangerous co-infections in HIV/AIDS patients. It is
estimated that one-third to one-half of the over 30 mil-
lion AIDS death can be ascribed to TB. Especially in
the endemic regions, Mtb and HIV co-infection ham-
pers control of both diseases. Thus, it is of relevance to
verify whether vaccines or immunotherapies against
HIV infections can be safely administered to individuals
infected by Mtb. In fact, the lack of this information has
prevented enrollment of HIV-1 infected individuals with
active TB in the Tat vaccine therapeutic trial conducted in
South Africa [18], (ISS T-003, ClinicalTrial.gov identifier:
NCT01513135).
Thus, to start addressing the interplay and reciprocal
effect of Tat vaccination on Mtb infection, we investi-
gated the effects of Tat vaccination on the outcome of
active Mtb infection and on the protective efficacy of
Bacillus Calmette-Guerin (BCG), the current TB vaccine,
in a murine TB model. The immunogenicity of the Tat
vaccine in these contexts was also assessed.
Methods
Microorganims
M. tuberculosis H37Rv (ATCC 27294) and M. bovis BCG
strain Pasteur (ATCC 27291) were grown at 37 °C in
Middlebrook 7H9 medium supplemented with albumin-
destrose-catalase enrichment, under agitation (120 rpm),
up to mid-exponential phase. Aliquoted stocks were
stored at −70 °C until use.
Reagents
HIV-1 Tat protein from IIIB-BH-10 (subtype B) strain
was produced in Escherichia coli and prepared as previ-
ously reported [20]. The lipopolysaccharide content of
this preparation was measured by a Lymulus amebocyte
lysate test and shown to be <0.06 EU/μg of protein.
The recombinant (r)Ag85B protein was prepared as
previously reported [21]. The lipopolysaccharide con-
tent of this preparation was measured by a Lymulus
amebocyte lysate test and shown to be below 4.3 EU/μg
of protein. All these reagents were purchased from
Diatheva, (Fano, PU, Italy). Purified protein derivative
(PPD) was purchased from Statens Serum Institute,
(Copenhagen, Denmark).
Experimental design
C57BL/6 female mice were supplied as specific
pathogen-free mice by Charles River (Calco, Lecco,
Italy) and were maintained in specific-pathogen-free
conditions. Food and water were available ad libitum.
According to the experimental design drawn in Fig. 1,
4 weeks old mice were immunized with a single dose
of BCG (105 CFU) injected subcutaneously. After five
weeks, BCG-vaccinated and unvaccinated mice were
challenged intravenously (i.v.) in a lateral tail vein
with 105 CFU of Mtb H37Rv. Infection studies were
performed in a biosafety level 3 facility; mice were
housed in microisolator cages and fed with autoclaved
food and water at libitum. Tat protein (10 μg/100 μL
of a buffer containing 0.5 % albumin) was injected
intradermally at 1, 2 and 5 weeks after the Mtb chal-
lenge. Mice treated only with buffer served as control.
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BCG and Tat protein were also administered, with
identical timing, to Mtb-free mice, as controls. Thir-
teen weeks after BCG vaccination, corresponding to
8 weeks post Mtb-infection and 4 weeks after the last
Tat administration, all uninfected and Mtb-infected
mice were sacrificed by cervical dislocation, according
to the ethics requirements. The degree of pathology
and levels of specific anti-Mtb or anti-Tat immune
responses were evaluated. Five or six mice were used
for each experimental mouse group. In total we used
66 mice.
Histology and morphometry
All right lung lobes from each mouse were fixed in
buffered formalin and subsequently embedded in par-
affin; the tissue was then cut in 5-μm sections. For
morphometry, 5-μm sections of entire paraffin-
embedded lung lobes were stained with hematoxylin-
eosin, were magnified at 2 and 40× by use of a Leica
DM LB microscope, and were photographed by an
HV-C20A camera (Hitachi). The histopathological pa-
rameters were evaluated and granuloma formation
was scored by estimating the area occupied in the
lung section. Appropriate software (Scion Image;
Scion) was used to measure both the total and the in-
filtrated area across the whole lobe of the lung. All
sections were evaluated in a blinded fashion by 2
investigators.
Lung homogenates
Lung homogenates were prepared by mechanical
homogenization of the left lobe of lungs in distilled
water containing 0.01 % Tween 80 and protease inhibi-
tors (complete Mini, Roche Diagnostic, Indianapolis, IN,
USA) using a Gentle Macs dissociator (Miltenyi Biotec
Srl, Calderara di Reno, Italy). Lung homogenates were
used freshly for CFU assay; the homogenate was spun
free from any debris by centrifugation and the super-
natant filtered before being assayed for cytokine
detection.
Spleen cell preparation
Single cell suspension from spleens were prepared in
2 ml of PBS by mechanic dissociation (Gentle Macs
dissociator); 200 μl were used freshly for CFU assay,
the left was applied to Falcon 2360 cell strainers (BD
Discovery Labware, San Diego, CA), centrifuged,
separated into aliquots and frozen for use in im-
munological assays.
CFU assay
The number of bacteria in lung homogenates or in
spleen cell suspensions after lysis with saponin 0.1 % in
Fig. 1 Schematic diagram of the experimental design. C57BL/6 female mice (6 mice/groups) were vaccinated subcutaneously with a single dose of
BCG Pasteur (105 CFU). Five weeks later, BCG-vaccinated and unvaccinated mice were challenged i.v. with 105 CFU of Mtb H37Rv. The Tat protein
(10 μg/mouse) in albumin buffer, or albumin buffer only were administered intradermally at 1, 2 and 4 weeks post Mtb infection. As control, some mice
(5 mice/groups) were either vaccinated or not with BCG, were not challenged with Mtb (Mtb-free mice), but received the Tat protein or albumin buffer
with a schedule identical to that of Mtb-infected mice. At 8 weeks post Mtb infection and 13 weeks post BCG vaccination, all mice were killed and the
Mtb-related pathology and immune response against Mtb antigens or Tat protein were evaluated
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distilled water was enumerated by plating 10-fold dilu-
tions, prepared in distilled water, on Middlebrook 7H10
agar. The colonies were counted visually after 21 days of
incubation.
Cell cultures
Spleen cells from both uninfected and Mtb-infected
mice were cultured in 96-well plates (4x105 cells/well) in
RPMI-1640 supplemented with 10 % heat-inactivated
FBS, 2 mM L-glutamine, 10 mM HEPES buffer, 50 μM
2-mercaptoethanol. Fifty U/ml penicillin and 50 μg/ml
streptomycin were added to cultures of cells from unin-
fected mice. Cells were stimulated with 5 μg/ml rAg85B
protein, 2 μg/ml PPD for 96 h, before detection of Inter-
feron (IFN)-γ and Interleukin (IL)-17 production in
culture supernatants.
Cytokine detection
Supernatants of spleen cell cultures and lung homoge-
nates were assayed for cytokine/chemokines detection
by quantitative sandwich ELISA specific for IFN-γ, IL-
17, IL-1β, IL-22 and Chemokine (C-C motif ) ligand-4
(CCL-4) (mouse Quantikine, R&D System, Inc.), in
accordance with manufacturer’s instructions.
Antibody measurement
The levels of total anti-Tat IgG antibodies in the sera
collected by retro-orbital bleeding were determined by
ELISA, as previously described [22]. Briefly, polyvinyl
microtiter plates (Nunc) were coated overnight at 4 °C
with 100 ng of Tat/well in 200 μL of 0.05 mol/L carbon-
ate buffer (pH 9.6). Plates were blocked with PBS con-
taining 1 % bovine serum albumin (BSA) and 0.05 %
Tween 20 or milk 1 % and several dilutions of mouse
sera were then incubated for 90 min at 37 °C. Horserad-
ish peroxidase-conjugated goat μ-Mouse IgG (Sigma)
and then ABTS solution (Roche Diagnostic SpA) were
used for anti-Tat IgG detection. The mean absorbance of
1/100-diluted, naïve, uninfected mouse sera plus 3
standard deviations was adopted as the cutoff absorb-
ance for determining antibody titers.
Statistical analysis
GraphPad Prism 6 Software was used to perform
one-way or two-way ANOVA and Tukey’s multiple
comparisons post-test. A P-value of < 0.05 was consid-
ered significant.
Results
Tat protein vaccination is well tolerated in both
Mtb-infected and Mtb-free mice
Mice were infected with virulent Mtb by i.v. route
5 weeks after BCG vaccination. Tat protein was
injected intradermally at 1, 2 and 4 weeks after Mtb
challenge with a protocol of administration
resembling that used in the clinical trials [12–15].
The scheme of the experimental design is illustrated
in Fig. 1.
Vaccination with Tat protein was well tolerated in both
Mtb-infected and Mtb-free mice, irrespective of BCG
vaccination. No evidence of toxicity, as judged by mor-
tality, body weight, food consumption, behavioral and
gross examination of vital organs at the time of sacrifice
was observed in Tat-treated Mtb-free mice (data not
shown). In Mtb-infected mice, all those parameters were
comparable among Tat-treated, buffer-treated and
untreated groups (data not shown).
Administration of Tat protein to Mtb-infected mice
reduces lung immunopathology without affecting
bacterial load
Tat vaccination did not affect the bacterial load in
both lungs and spleens of Mtb-infected mice (Fig. 2a,
b). The Tat-treated group showed only a slight and
non-significant reduction in CFU levels compared to
untreated or buffer-treated, Mtb-infected mice,
(Fig. 2a, b). Of note, administration of Tat protein re-
duced Mtb-driven lung immunopathology. When lung
sections were examined microscopically, untreated
mice were found to develop larger areas of inflamma-
tory infiltration than Tat-treated mice (Fig. 2c); in
particular, the cellular infiltrates in the total area of
lung sections, which was 31 ± 2.6 % in untreated
mice, almost halved (18.7 ± 3.2 %) in Tat-treated mice
(Fig. 2d). Lungs of Mtb-infected mice, irrespective of
Tat-treatment showed a nodular and diffuse infiltra-
tion in the peribronchial, perivascular and septal
interstitial space, with the infiltration also present in
the alveolar spaces. Also the cell composition of
granulomatous lesions was similar among the groups
of Mtb-infected mice. It consisted mainly (60-70 %)
of epitheliod macrophages sometimes with eosino-
philic cytoplasm, sometimes with clear vesicular de-
generation and foamy appearance (Fig. 2c), and the
remaining 30-40 % represented by lymphocytes and
rare neutrophils. No necrotic core or destruction of
the lung parenchima was present.
In agreement with histological examination, Tat
vaccination lowered the protein levels of IFN-γ,
CCL-4 and IL-1β, in the lungs of Mtb-infected mice
(Fig. 3a-c). Elevated pulmonary amounts of these
Mtb-induced cytokines/chemokines correlate with a
more severe outcome during the chronic phase of
Mtb infection [23, 24]. In contrast, Mtb infection did
not induce expression of IL-17 and IL-22 whose low
levels remained unaltered in the lungs upon Tat
administration (Fig. 3d, e).
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Protection against Mtb infection conferred by the BCG
vaccine remains good in mice receiving Tat protein
vaccine
We evaluated whether the administration of Tat vac-
cine could alter the protection conferred by BCG, the
gold standard TB vaccine. Respect to unvaccinated
mice, BCG vaccination significantly reduced the bac-
terial load in both lungs and spleen (Fig. 2a, b), de-
creased areas of inflammatory infiltration (Fig. 2c, d),
and lowered the lung levels of IFN-γ, IL-1β and CCL-
4 (Fig. 3a-c). The BCG-mediated protective effects
were maintained in mice receiving Tat vaccination
post Mtb-infection. No significant differences were
observed among the three BCG-vaccinated, Mtb-in-
fected groups in terms of bacterial loads (Fig. 2a, b)
and cytokine/chemokine expression in the lungs
(Fig. 3a-e). Of note, administration of Tat protein fur-
ther reduced the area of inflammatory infiltration,
suggesting a beneficial effect on lung pathology devel-
opment (Fig. 2c, d).
Administration of Tat vaccine enhances the level of IL-1β
in the lungs of both unvaccinated and BCG-vaccinated,
Mtb-free mice
Lungs of Tat-treated, Mtb-free mice showed a normal tis-
sue architecture and the absence of notable inflammatory
Fig. 2 Tat vaccine administered to Mtb-infected mice reduces pulmonary infiltration and does not abrogate the protection conferred by BCG
vaccination. Eight weeks post Mtb infection, bacteria in the lung (a) and spleen (b) were enumerated by CFU assay in mice treated as shown in
Fig. 1. c Comparison of percentages of infiltrated area of sections of lung right lobes from the different mice groups. All data are expressed as
mean of 6 individual mice/group ± SE. Statistical analysis was done by one-way ANOVA and Tukey’s multiple comparisons post-test *, P < 0.05, **,
P < 0.01, ***, P < 0.001, differences respect to untreated Mtb-infected group. In panel C, the difference between BCG and BCG Tat-treated group is
indicated. d Hematoxylin-eosin–stained sections of paraffin-embedded lungs from Mtb-infected mice killed at the 8 weeks post infection (upper
panel) (magnification, ×2) and (lower panel) (magnification, ×40)
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infiltrates by histological examination (data not shown).
The protein levels of IFN-γ, CCL-4, IL-17 and IL-22 were
comparable among Tat-treated, buffer-treated and un-
treated, Mtb-free mice (Fig. 3f). Instead, the expression of
IL-1β, a pro-inflammatory cytokine contributing to host
immune defense against Mtb [23, 25], was significantly
up-regulated by Tat vaccine administration.
In the lungs of Mtb-free mice, BCG vaccination in-
duced the expression of IFN-γ (Fig. 3f ) and the appear-
ance of small inflammatory infiltrates consisting of
lymphocytes (the prevalent cell type) and macrophages
(data not shown). Tat vaccination did not affect the ex-
pression of IFN-γ and the mild inflammation triggered
by BCG, while increased the protein level of IL-1β
(Fig. 3f ), as found in unvaccinated, Mtb-free mice
(Fig. 3f ).
Administration of Tat vaccine enhances mycobacterial-
specific IFN-γ and IL-17 responses in mice infected with
Mtb and in Mtb-free mice vaccinated with BCG
We evaluated the effect of Tat vaccination on the develop-
ment of systemic Mtb-specific immune responses, focusing
on IFN-γ, which is essential for control of Mtb infection
[26, 27] and IL-17, which appears to play a protective role
in the early phase of Mtb infection [28]. Spleen cells recov-
ered from both Mtb-infected and Mtb-free mice were
stimulated ex vivo with Ag85B, an immunodominant anti-
gen with a role in TB protection [21, 29–31], or PPD, the
Fig. 3 Lung protein levels of IFN-γ, CCL-4 and IL-1β are lowered in Tat-vaccinated, Mtb-infected mice. Left lungs of Mtb-infected (a-e) or uninfected (f)
mice treated as reported in Fig. 1 were homogenized and then assayed for detection of the indicated cytokine/chemokine by commercial ELISA kits. In
plots A-E, the dotted line represent the mean protein levels of the specific cytokine/chemokine detected in lung homogenate of untreated Mtb-free mice.
All data are expressed as mean of 6 or 5 individual mice/group ± SE. Statistical analysis was done by one-way ANOVA and Tukey’s multiple comparisons
post-test *, P< 0.05, **, P< 0.01, ***, P< 0.001, differences respect to untreated Mtb-infected group (a-e) or to untreated Mtb-free group (f). In panel F, the
differences between BCG Tat-treated group versus both BCG and BCG buffer groups are indicated
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mixture of antigens released by Mtb during in vitro growth.
Splenocytes of all groups of mice infected with Mtb pro-
duced significant amounts of IFN-γ, but not IL-17, in re-
sponse to both Ag85B and PPD stimulation (Fig. 4a, b). Tat
vaccine administration to Mtb-infected mice enhanced
antigen-specific IFN-γ responses triggered by infection and
even induced the production of IL-17 (Fig. 4a-c).
However, the Tat-mediated immunomodulatory effects
were not observed in BCG-vaccinated, Mtb-infected
mice (Fig. 4a-c). Irrespective of Tat administration, no
IFN-γ or IL-17 responses specific for mycobacterial
antigens were detected in unvaccinated Mtb-free mice
(Fig 4d-f ). Instead, Tat protein administration potenti-
ated the low mycobacterial-specific IFN-γ and IL-17
responses elicited by BCG vaccination in Mtb-free
mice (Fig. 4d-f ).
The infection with Mtb reduces but does not suppress the
production of anti-Tat antibodies which even is increased
by BCG-vaccination in Mtb-free mice
Finally, we determined whether mice infected with Mtb
and vaccinated with Tat developed anti-Tat antibodies, a
key parameter to evaluate the immunogenicity of the Tat
vaccine and a bona fide correlate of efficacy [8, 14, 18, 32].
Mice receiving Tat vaccine post-Mtb infection were still
able to mount a specific humoral response against Tat
(Fig. 5a). The titers of anti-Tat IgG detected in sera of Tat-
treated, infected mice (Fig. 5a), were only slightly lower
than those measured in Tat-treated, Mtb-free mice
(Fig. 5b). In Tat-treated, Mtb-infected mice, BCG vaccin-
ation did not affect the production of anti-Tat antibodies
(Fig. 5a). On the other hand, in Mtb-free mice, a BCG
priming before administration of Tat vaccine (the BCG
Fig. 4 Tat vaccine enhances systemic IFN-γ and IL-17 responses specific for mycobacterial antigens in both Mtb-infected and BCG-vaccinated,
Mtb-free mice. Spleen cells of Mtb-infected (a-c) or Mtb-free (d-f) mice treated as shown in Fig. 1 were stimulated ex vivo with 5 μg/ml of rAg85B
protein or 2 μg/ml of PPD for 96 h. Culture supernatants were assayed for production of IFN-γ (a, d, Ag85B stimulation; b, e, PPD-stimulation) or
IL-17 (c, f) by commercial ELISA kits. Each data point represents a pool of 5 or 6 mice, assessed in technical duplicates or triplicates and represents
the mean ± SEM. The results shown are representative of two independent experiments. Statistical analysis was done by two-way ANOVA and
Tukey’s multiple-comparison post-test*, P < 0.05, **, P < 0.01, ***, P < 0.001, ****, P < 0.0001, differences respect to untreated Mtb-infected group
(a-c) or to untreated Mtb-free group (d-f). In panels d-f, the differences between BCG Tat-treated group versus both BCG and BCG buffer groups
are indicated
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vaccinated, Tat-treated group) potentiated the production
of IgG specific for Tat respect to unvaccinated, Tat-treated
mice (Fig. 5b).
Discussion
The HIV-1 Tat protein-based vaccine, a promising thera-
peutic vaccine for AIDS patients, is in advanced clinical
development [18, 19], (ISS T-003, ClinicalTrial.gov iden-
tifier: NCT01513135). Here we show that the adminis-
tration of Tat vaccine to mice infected with Mtb, the
main coinfection of AIDS, was well-tolerated, immuno-
genic, did not abrogate the protective efficacy of BCG,
the current TB vaccine, and, overall, reduced the lung
immunopathology caused by Mtb.
Tat protein vaccine did not affect bacterial growth in
mice infected with Mtb. The scarce influence of Tat vac-
cine on bacterial load was in line with the results
obtained in mice primed at 7 weeks post-Mtb infection
with a MultiHIV DNA/protein vaccine encoding several
HIV-1 products, including Tat [33] and with the out-
come of Mtb H37Rv infection of Tat-transgenic mice,
showing a lung bacterial burden comparable to that
found in non-transgenic littermates [34]. However, Mtb
growth is just one of the events that determine TB path-
ology. The immunocompetent C57BL/6 mice used in
this study are able to contain Mtb replication in the
lungs upon the initial exponential Mtb growth but can-
not control the immuno-mediated lung pathology, which
progressively worsens and causes death [35]. In this con-
text, the Mtb-triggered expression of IFN-γ, IL-1β and
CCL-4 in the lungs [23] plays a dual, opposite role. In
the early stage of infection, these pro-inflammatory cyto-
kines/chemokines trigger protective mechanisms [23],
while their persistence in the late stages, indicates the
inability of controlling/clearing the infection and repre-
sents a major marker of progressing TB [24]. Unexpect-
edly, we found that Tat protein vaccination, when
compared to untreated mice, limited Mtb infection-
driven lung immunopathology by reducing both the pro-
tein levels of IFN-γ, IL-1β and CCL-4 and the area of
cellular infiltration. When the Mtb/Tat-treated group
was compared to the Mtb/buffer group differences were
less evident with regard to the infiltrated area, while dif-
ferences remained significant with respect to the reduc-
tion of cytokine/chemokine levels, confirming the ability
of Tat vaccine to improve lung immunopathology.
Since containment of lung damage occurred independ-
ently from bacterial load control, it is conceivable that
Tat-treatment affected immune/inflammatory mecha-
nisms driven by the infection but not closely related to
Mtb active replication. Of note, incapacity to control
progression of lung disease due to an unstoppable in-
flammation despite containment of Mtb load is a key
feature of TB pathology in these mice [35]. We know lit-
tle about the sustainability and mechanisms involved in
Tat mediated-improvement of lung pathology. However,
the Tat-mediated protective/immunosuppressive effects
persisted up to study completion, that is 4 weeks after
the last Tat dose, and were independent of IL-17/IL-22
axis and lung neutrophil influx, which cause the high
susceptibility to Mtb infection in mice [36]. The contain-
ment of excessive Mtb-triggered inflammatory responses
is a novel, and thus far unreported, feature of Tat-
mediated immune-modulatory capabilities, which may
have important implications in public health. Control of
excessive inflammation to prevent lung damage is rele-
vant in human pulmonary TB [37] and correlates with a
better prognosis and efficacy of chemotherapy in TB
patients [38].
In sharp contrast with our findings, Tat has been reported
to favor TB progression [34]. In particular, an accelerated
mortality rate, poorly organized lung granuloma-lesions
and increased IFN-γ and TNF-α expression as signs of the
worsening outcome have been reported in Tat transgenic
mice [34]. However, differences between our model of Tat
protein vaccination and the Tat transgenic mouse model
Fig. 5 Tat vaccine administered to Mtb-infected mice is immunogenic. Serum samples of Mtb-infected (a) or Mtb-free (b) mice treated as shown in
Fig. 1 were analyzed by ELISA for the presence of anti-Tat antibodies. Data are plotted as geometric mean ELISA titer ± SEM of 5 or 6 individual mice/
group. The results shown are representative of two independent experiments. Statistical analysis was done by one-way ANOVA and Tukey’s multiple
comparisons post-test *, P < 0.05, **, P < 0.01, ***, P < 0.001, differences respect to untreated Mtb-infected group (a) or to untreated Mtb-free group
(b). In panel b, the difference between BCG-vaccinated and unvaccinated, Tat-treated groups is indicated
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are substantial, and may explain the discrepancy of results.
In Tat-transgenic mice, Tat is permanently expressed in
large amounts in all tissues, and can be found both intra-
and extra-cellularly. More importantly, Tat-transgenic mice
are tolerant to Tat and do not mount an anti-Tat immune
response. To the opposite, in our vaccine model tiny
amounts of Tat protein were administered a few times in
mice, which mounted an antibody response to the protein.
Thus, in our model, exposure to Tat was much lower and
shorter, and further reduced by the ensuing antibody re-
sponse, as compared to Honda's transgenic one [34].
In Tat-vaccinated, Mtb-infected mice, the reduction of
both bacterial load and lung immunopathology con-
ferred by BCG was maintained, indicating that Tat treat-
ment did not abrogate the vaccine efficacy of BCG. Our
data provide preliminary evidence for the use of Tat vac-
cine in those countries with high HIV/TB co-endemicity
and where BCG vaccination is mandatory [39]. BCG,
given to over 3 billion individuals, in the setting of rou-
tine newborn immunization in high endemic TB coun-
tries, is effective in controlling the severe forms of
pediatric TB [39], although unable to control pulmonary
TB in adult patients [40].
Tat vaccination in Mtb-infected mice potentiated sys-
temic IFN-γ and IL-17 responses specific for mycobac-
terial antigens, including Ag85B. The ability of Tat to
activate antigen unrelated Th1 responses is well known,
and several of the involved mechanisms have been
described [20, 41–44]. Tat protein alters lymphocyte
signaling (e.g. activation of NF-kB), modulates dendritic
cell maturation, enhances antigen processing and pres-
entation and promotes the induction and effector func-
tions of memory T cells [20, 41–44]. Instead, little it is
known about the Tat-mediated modulation of IL-17 re-
sponse. Recently, it has been reported that Tat increases
IL-17 production by T cells, via activation of the vascu-
lar endothelial growth factor receptor 2 [45]. Since
Ag85B-specific CD4+ T cells are induced to produce
IL-17 through antigen-unrelated activation of dendritic
cells, particularly of the CD8α− subtype [46], we cannot
exclude that, in our model, Tat promoted IL-17
response via its known ability to activate dendritic cells
[20, 41]. Whether the Tat-mediated modulation of
mycobacterial-specific IFN-γ and IL-17 responses
might have contributed to lowering lung immunopa-
thology remains to be investigated. It is known that
protection from Mtb infection is dependent on robust
IFN-γ secretion by antigen-specific CD4+ T cells [26]
and, to a lesser extent, on Th17 responses [28]. In par-
ticular, activation of IFN-γ response specific for Ag85B,
a leading TB vaccine candidate [29], (http://www.clini
caltrials.gov/show/NCT01049282), results in a better
control of Mtb infection in numerous experimental
animal models [21, 30, 31].
Curiously, the Tat-mediated enhancement of immune
responses was observed in unvaccinated, Mtb-infected
mice and BCG-vaccinated uninfected mice, but not in
BCG-vaccinated, Mtb-infected mice. This finding was
unexpected, and we do not have a definitive explan-
ation for it. It is conceivable that this latter condition, a
recall response to BCG triggered by an acute Mtb infec-
tion, markedly differs, with respect to either BCG vac-
cination (untriggered memory) or Mtb infection alone
(primary response), in terms of antigen load, inflamma-
tory environment and quality of adaptive and/or innate
immune responses.
In addition to the modulation of the adaptive re-
sponse, Tat may improve the control of Mtb-mediated
lung immunopathology by affecting innate immunity. In
the lungs of Mtb-free animals vaccinated with Tat, a sig-
nificant increase of IL-1β was found 4 weeks after the
last Tat dose. Interleukin-1β is important for host im-
mune defense against Mtb [23, 25], likely increasing the
mycobactericidal activity of macrophages [47], the main
cell type harboring the pathogen.
Finally, we evaluated the impact of Mtb infection and/
or BCG vaccination on the development of anti-Tat anti-
bodies, a key parameter to evaluate immunogenicity of
the Tat vaccine and a bona fide correlate of HIV vaccine
efficacy [8, 14, 18, 32]. Mtb infection only slightly
reduced the production of specific anti-Tat IgG. Similar
results were observed in Mtb-infected mice vaccinated
with a MultiHIV DNA/protein vaccine, which included
Tat [33]. The moderately high titer of anti-Tat serum
IgG elicited by this vaccine was not altered by the con-
current Mtb infection, despite an impairment in both
the magnitude and quality of antibodies against other
vaccine components (p24 Gag and gp160 Env) [33].
Altogether, these data indicate that Mtb-infected hosts
are still able to mount a humoral response against the
Tat vaccine, a mandatory step for vaccine efficacy. How-
ever, it remains to be determined whether the anti-Tat
antibodies elicited in the presence of Mtb-infection are
effective at neutralizing the biological activities of Tat, as
required for Tat vaccine efficacy [14, 32].
In Tat-vaccinated, Mtb-free mice, a priming with BCG
increased the production of anti-Tat antibodies. Likely,
this effect was due to the “adjuvant” capabilities of this
live non-pathogenic vaccine. Indeed, BCG has been used
to treat non-muscle-invasive bladder cancer for more
than 30 years [48], being one of the most successful
biotherapies for cancer in use [49]. BCG triggers the
secretion of pro-inflammatory cytokines [50], modulates
the activation of granulocytes, macrophages, and den-
dritic cells [51, 52] and promotes bystander activation of
CD4+ and CD8+ lymphocytes [53]. In line with those
findings, we observed signs of a very mild inflammation in
the lungs of BCG vaccinated, Mtb-free mice, highlighted
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by the presence of small foci of infiltrates and by the ex-
pression of IFN-γ as late as 13 weeks after the subcutane-
ous BCG inoculum. The concurrent Mtb infection
subverted the BCG-mediated increase of anti-Tat anti-
bodies. It is conceivable that the inflammatory/immune
responses triggered by the virulent Mtb, and mitigated
only in part by BCG vaccination, were predominant, and
abrogated the BCG-mediated “adjuvant” effects.
Although the route of Mtb infection used in our stud-
ies is unnatural, reports from several studies indicate
that Mtb-driven pulmonary pathological events, such as
granuloma formation and expression of cytokines/che-
mokines as well as vaccine efficacy, are comparable in
mice infected with Mtb either by i.v. or by aerosol route
[54–56]. Accordingly, although confirmation of our
results in mice challenged by the aerosol route is war-
ranted, we are confident that the i.v. route did not invali-
date the significance of our findings. Moreover, given the
high proportion of individuals with active TB in coun-
tries where HIV-1 is highly prevalent, it will be of
importance to assess in future studies whether Tat vac-
cination is beneficial also during anti-TB chemotherapy.
Conclusions
The anti-HIV Tat protein vaccination administered to
mice infected i.v. with Mtb: 1) did not favour Mtb replica-
tion; 2) limited the pathogen-driven immuno-mediated
lung injury for at least 4 weeks after the last Tat dose; 3)
did not abrogate the protective efficacy of BCG, the
current TB vaccine; 4) enhanced early systemic Mtb-
specific IFN-γ responses, essential for control of Mtb
infection; 5) was immunogenic, as indicated by the
production of anti-Tat antibodies; 6) was well tolerated. In
addition, BCG vaccination enhanced the anti-Tat specific
humoral response in Tat-vaccinated, Mtb-free mice. Our
findings provide preliminary evidence of the feasibility, in
terms of safety and immunogenicity, of administering the
Tat vaccine in BCG-vaccinated and/or Mtb-infected
subjects. These results are of clinical relevance considering
that people who mostly need vaccines against HIV/AIDS
live in geographical areas where TB is highly prevalent.
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